Dicynone tablets 250 mg #10

Dicynone tablets 250 mg #10
Manufactured by: Slovenia
Product Code: 13013

Qty:  BUY
You can buy Dicynone tablets 250 mg #10 here.


Pharmacological properties:
Pharmacodynamics. Dicynone is a means to prevent and stop bleeding. It affects the first stage of the mechanism of hemostasis (the interaction between the endothelium and platelets). Increased platelet adhesiveness Dicynone, normalizes the stability of the capillary walls, thus reducing their permeability, inhibits the biosynthesis of prostaglandins, which cause platelet disaggregation, vasodilation and increased capillary permeability. As a result, the bleeding time is significantly reduced blood loss is reduced.
Pharmacokinetics. Etamzilat almost completely absorbed in the gastrointestinal tract, reaching a Cmax in serum within 4 h after administration.
Following in / injection hemostatic effect observed after 5-15 min, the maximum is reached within 1 h drug is effective for 4-6 hours, after which the effect gradually disappears. After the on / in a Dicynone 500 mg maximum plasma levels achieved after 10 minutes and 50 ug / ml.
Approximately 72% of the administered dose was excreted within the first 24 h in the urine in unchanged condition. Etamzilat crosses the placental barrier and passes into breast milk.
Dicynone indicated for the prevention and control of hemorrhage in the superficial and inner capillaries of different etiologies, especially if the bleeding is due to endothelial damage:
• prevention and treatment of bleeding during and after surgical procedures in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery;
• prevention and treatment of capillary hemorrhage of various etiology and localization: hematuria, metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives, nosebleeds, bleeding gums.
Besides the p-p for injection:
• Neonatology: prevention of periventricular haemorrhage in preterm infants.
Applied inside. Tablets are taken during or after a meal.
The daily dose for adults is 1-2 tablets 3-4 times per day. In severe cases the dose is 3 tablets 3-4 times per day.
When menorrhagia is prescribed 3-4 pills a day, starting with the 5th day of the expected start of menstruation until the 5th day of the next menstrual cycle.
After the operation, use 1-2 tablets every 6 hours until the disappearance of the risk of bleeding.
The daily dose for children is half the adult dosage.
P-P Injection
Apply in / in (slow) or / m The optimal dose for adults is 10-20 mg / kg etamzilata and injected into 3-4 hours. In most cases, the daily dose is 1-2 capsules 3-4 times per day. The daily dose for children is half the adult dosage.
Before surgical intervention is introduced into / or / m 1-2 ampoules. During the operation, type in / 1-2 capsules, the introduction of the same dose can be repeated. After surgery, 1-2 ampoules administered every 6 h until the disappearance of the risk of bleeding.
In neonatology Dicynone injected i / m or / in doses of 12.5 mg / kg (0.1 ml = 12, 5 mg). Treatment should begin within the first 2 h after birth. The introduction of the drug conducted every 6 hours for 4 days to a total dose of 200 mg / kg.
Dicynone can be applied topically (skin graft, removal of a tooth) with a sterile gauze soaked in preparation.
Hypersensitivity to etamzilat or any other ingredient of the drug. Acute porphyria, increased blood clotting. Hemoblastosis (lymphatic and myeloid leukemia, osteosarcoma) in children; pp injection: hypersensitivity to sodium sulfite; asthma.
The nervous system: seldom - headache, dizziness, flushing of the face, paresthesia in the lower extremities.
Since the cardiovascular system: very rarely - thromboembolism, arterial hypotension.
Gastrointestinal disorders: nausea, pain in the epigastrium.
By the immune system: rare - allergic reactions, skin rash, described a case of angioedema.
Part of the endocrine system: very rarely - acute porphyria.
On the part of the musculoskeletal system: seldom - back pain.
All side effects are mild and transient.
The children who were treated etamzilat to prevent bleeding in acute lymphoid and myeloid leukemia, severe leukopenia often noted.
used with caution in patients with thrombosis or thromboembolism. The drug is not effective for thrombocytopenia.
Before treatment is necessary to exclude other causes of bleeding.
Each tablet contains 60.5 mg of Dicynone lactose, therefore patients with hereditary galactose intolerance, lactase deficiency, malabsorption syndrome, glucose / galactose should not be prescribed this drug.
Do not use the drug in case of changing the color of injecting r-ra.
P-p Dicynone is not compatible with the p-rum sodium bicarbonate and sodium lactate powder.
Use during pregnancy and lactation.
Safety of etamzilata during pregnancy has not been established. Therefore Dicynone prescribed only if the expected benefit to the mother outweighs the potential risk to the fetus.
During treatment Dicynone should stop breast-feeding.
Children. The drug is contraindicated in children with Leukemia (lymphatic and myeloid leukemia, osteosarcoma).
The ability to influence the reaction rate while operating a vehicle or operating other machinery. It has no effect.
Tablets: interaction with other drugs have not been established.
P-P Injection: The contents of the ampoule should not be confused with other drugs in the same syringe. If Dicynone mixed with physiological p-rum, it should be used immediately.
no data.
in a dry, dark place at temperatures above 25 ° C.

Write a review

Note: this form is for product reviews only. To contact us please use contact page.

Your Name:

Your Review: Note: HTML is not translated!

Rating: Bad            Good

Enter the code in the box below: